BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits ...
Data indicates a favorable safety and tolerability profile for CC-42344, with no serious adverse events or drug-related discontinuations reported. Extension of enrollment in the Phase 2a study allows ...
BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam ...
LONDON--(BUSINESS WIRE)--EMMAC Life Sciences Ltd (“EMMAC” or the “Company”), the European independent medical cannabis company, announces that it has entered the German medical cannabis market through ...
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent ...
Acquisition adds new vertical and strategic operations in key region of global growth strategy LEAMINGTON, ON, Nov. 8, 2018 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) ...
LEAMINGTON, ON, Jan. 9, 2019 /PRNewswire/ - Aphria Inc. ("Aphria" or the "Company") ( and NYSE: APHA) today announced that it had completed its previously announced acquisition of ("CC Pharma"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback